Novo Nordisk stock steadies as Wegovy pill trial targets lower maintenance doses
Published on 08/21/2026 at 18:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk A/S (ISIN DK0062498333) stock is trading sideways after Q2 2026 earnings while investors weigh a new Phase 3 OASIS 5 study that is testing lower maintenance doses of the company’s oral Wegovy obesity pill as of August 21, 2026.
The shares closed at $46.14 on the New York Stock Exchange on August 20, 2026, down 0.73% on the day, before ticking to $46.11 in pre-market trading on August 21, 2026, according to market data. Year to date, the stock shows a negative total return of 5.42% versus a 4.35% gain for its OMX Copenhagen 25 benchmark, highlighting how Novo Nordisk has lagged its home index in 2026.
Q2 2026 earnings show GLP-1 strength but mixed market reaction
Recent corporate news indicates that Novo Nordisk’s latest quarter featured strong expansion in GLP-1 based treatments for diabetes and obesity, but the market response has been cautious as pricing pressures and competition come into sharper focus.
In its Q2 2026 results, Novo Nordisk reported adjusted operating profit of DKK 33,389 million for the quarter and raised its outlook for 2026 adjusted sales and adjusted operating profit, according to a recent corporate release featured in a financial news overview. The upgrade to full-year guidance underscores management’s confidence that demand for GLP-1 drugs such as Ozempic and Wegovy can offset higher investment needs and competitive challenges.
The guidance move did not translate into a sustained share price rally. Performance figures show that over the one-year period ending August 21, 2026, Novo Nordisk’s total return is down 12.64% while the OMX Copenhagen 25 index delivered an 11.88% gain in the same timeframe, underscoring how the stock has underperformed both on a year-to-date and 12-month basis. Over three years the picture is even starker, with Novo Nordisk down 45.85% versus an 8.91% gain for the benchmark, reflecting how expectations for GLP-1 growth have been recalibrated.
For investors, the combination of raised guidance and weaker share performance suggests that questions around valuation, margin durability and competition in obesity and diabetes are now central to the Novo Nordisk equity story.
OASIS 5 Wegovy pill study seeks lower doses
A fresh operational catalyst for Novo Nordisk in August 2026 is the start of a new late-stage trial evaluating lower maintenance doses of the company’s oral Wegovy semaglutide pill in obesity and overweight patients. A detailed report on drug development developments explains that Novo Nordisk has begun a placebo-controlled Phase 3 study designed to identify “the most optimal lower dose” of oral GLP-1 medicine for weight loss. The drug development article describes how the OASIS 5 trial will test two undisclosed oral doses of GLP-1 receptor agonist semaglutide in combination with diet and increased physical activity.
Under the current Wegovy pill label, Novo Nordisk advises patients to start with a 1.5 mg daily dose, use intermediate doses of 4 mg and 9 mg over the first 90 days, and then remain on a 25 mg maintenance dose. The OASIS 5 protocol is intended to assess whether lower long-term doses can maintain clinically meaningful weight loss while better reflecting patient needs in routine obesity management, including potential tolerability improvements and more efficient use of semaglutide.
Novo Nordisk currently markets 1.5 mg, 4 mg, 9 mg and 25 mg doses of oral semaglutide under the Wegovy brand for obesity. It also offers 3 mg, 7 mg and 14 mg oral semaglutide tablets for type 2 diabetes under the Rybelsus name, giving the company a broad portfolio of GLP-1 dosing options. Prior clinical programs, including the OASIS 4 and OASIS 1 trials, evaluated higher 25 mg and 50 mg doses for weight loss in people without diabetes, while earlier PIONEER studies looked at 7 mg and 14 mg doses in type 2 diabetes to assess blood sugar effects and weight outcomes.
Comparative data from these programs illustrate the trade-off between dose, efficacy and patient characteristics. In PIONEER 4, which assessed oral semaglutide in diabetes, 16% of patients receiving the drug had lost at least 10% of their body weight by week 52. In contrast, mid-stage OASIS 4 results released earlier in 2026 showed that 63% of participants achieved at least 10% weight loss by week 64 at a higher dose, although direct comparisons are complicated by differences in trial design and populations. Still, the numbers highlight that higher doses can yield stronger weight-loss outcomes at the cost of greater semaglutide consumption and potentially more side effects.
Mid-stage results in March 2026 indicated average weight loss of 10.7% after 42 weeks for oral semaglutide in a key OASIS program, which disappointed some investors as it trailed the up to 25% loss achievable with injectable GLP-1 therapies. Shares in the Danish biotech fell by roughly one third around that announcement, illustrating how sensitive the stock is to perceived gaps between oral efficacy and injectable benchmarks. Novo Nordisk’s CagriSema combination, by contrast, delivered average weight loss of 22.7% and was submitted to the US Food and Drug Administration in December 2025, reinforcing the idea that the company’s pipeline spans multiple dosage forms and combinations.
Strategically, identifying lower maintenance doses through OASIS 5 could help Novo Nordisk improve the economics of oral Wegovy. A previous earnings call commentary noted that patients taking injectable Wegovy typically use up to 7.2 mg of semaglutide per week, whereas oral Wegovy users may take up to 25 mg per day. That consumption pattern means the gross margin on oral Wegovy has been below that of the injectable form, making manufacturing efficiency and dose optimization critical levers for profitability.
Analysts have pointed out that the need to produce large quantities of semaglutide is a potential vulnerability for oral Wegovy, especially against rival oral GLP-1 therapies that are small molecules and cheaper to produce at scale. In the drug development report, one research commentary argued that a competing oral drug uses a small-molecule structure with higher margins, making price competition a significant risk for Novo Nordisk’s peptide-based oral therapy. Yet, sales data so far show that the Wegovy pill has outsold its main rival, helped by stronger perceived efficacy and brand recognition, even though no head-to-head trial has been conducted.
Legal and competitive backdrop for GLP-1 growth
The OASIS 5 initiative sits within a broader competitive and legal environment where Novo Nordisk is seeking to protect its intellectual property and maintain its lead in GLP-1 based therapies. A recent legal news update from India reports that the Delhi High Court on August 11, 2026, ordered Sun Pharma Laboratories Limited to seek prior court approval before commercially manufacturing or launching semaglutide tablets, in a patent infringement suit filed by Novo Nordisk A/S. The court decision requires Sun Pharma to obtain judicial clearance before entering the market with its semaglutide tablets.
This Indian case follows other legal steps by Novo Nordisk to limit the spread of unapproved or compounded GLP-1 formulations that could undermine patient safety and erode branded sales. On top of that, the company continues to face vigorous competition from other GLP-1 and dual-agonist drugs targeting obesity and diabetes, particularly from major peers in the United States. Oral obesity treatments, injectable weekly formulations, and combination therapies are all moving through late-stage development or have entered commercial markets, intensifying the race to capture long-term weight-loss and metabolic health spending.
At the same time, demand for GLP-1 drugs in everyday healthcare systems underscores the scale of the opportunity. A recent health policy article from Belgium notes that in 2025 more than 128,750 patients received reimbursement for GLP-1 based diabetes medicines, with Ozempic cited as the most recognized example from the Danish company. That growing reimbursement pool illustrates how GLP-1 medicines are becoming embedded in standard diabetes care, creating recurring revenue streams that support Novo Nordisk’s investment in obesity-specific brands like Wegovy and combo therapies such as CagriSema.
Share repurchases and capital return policy
Novo Nordisk’s capital allocation also plays into the stock’s appeal. A recent share repurchase announcement shows that as of August 7, 2026, the company had bought back 27,884,179 B shares since February 4, 2026 at an average price of DKK 279.01, for a total transaction value of DKK 7,780,067,909. The share repurchase programme confirms management’s ongoing commitment to returning capital to shareholders alongside investment in R&D and manufacturing capacity.
The scale of the buyback, which amounts to tens of billions of Danish kroner, signals that Novo Nordisk sees its shares as attractive at current levels and is willing to deploy significant resources to support long-term value. In the context of a stock that has fallen 5.42% year to date and 12.64% over 12 months, while trading at a forward price-to-earnings multiple of 13.72 compared with an industry average of 18.99 and a five-year company mean of 29.14, the repurchase programme can be read as a response to perceived undervaluation.
Recent equity research commentary indicates that earnings estimates for Novo Nordisk’s 2026 results have edged higher over the past 30 days, moving from $3.39 per share to $3.41 per share. That modest upward revision suggests that the analyst community is incrementally more optimistic about the company’s profit trajectory, even as share performance has lagged.
Viewed together, the guidance raise, buybacks and earnings estimate revisions form a coherent narrative: management is signaling confidence in GLP-1 driven growth, and external forecasts are moving up, yet the market is still discounting the stock relative to its own history and sector peers.
Representative product: Wegovy oral pill
Within Novo Nordisk’s portfolio, the Wegovy oral semaglutide pill is becoming a flagship product for obesity management with a distinctive dosing profile. The current approved regimen begins at 1.5 mg per day, increases stepwise through 4 mg and 9 mg, and eventually reaches a 25 mg maintenance dose. The OASIS 5 Phase 3 trial is intended to refine this maintenance stage by testing lower daily doses that could maintain weight-loss efficacy while reducing total semaglutide exposure.
Earlier trial data in OASIS programs and PIONEER studies have established that oral semaglutide can deliver double-digit percentage weight loss and significant glucose control improvements. The challenge now is to balance optimal efficacy against tolerability, manufacturing cost and payer willingness to fund long-term high-dose peptide therapy. If OASIS 5 demonstrates that a lower maintenance dose still delivers robust weight loss compared with placebo, Wegovy’s label could ultimately expand to include more flexible dosing options tailored to patient response and side-effect profiles.
Novo Nordisk stock price context
Novo Nordisk’s American depositary shares trade on the New York Stock Exchange under the ticker NVO. As of August 20, 2026, the shares closed at $46.14, with a small pre-market move to $46.11 noted on August 21, 2026. The latest performance overview shows trailing total returns of -5.42% year to date, -12.64% over one year, and -45.85% over three years relative to positive benchmark gains, illustrating a multi-year period of underperformance despite the high-profile growth of GLP-1 therapies.
For equity investors, the key tension now lies between Novo Nordisk’s operational momentum in obesity and diabetes - reinforced by raised 2026 guidance, scaled GLP-1 franchises, and clinical programs like OASIS 5 - and a valuation that has compressed well below industry averages and the company’s own historical multiples. The outcome of the Wegovy pill dosing studies, future regulatory decisions on combination therapies such as CagriSema, and the evolution of legal and competitive dynamics around semaglutide will all help determine whether Novo Nordisk stock can close its performance gap to broader indices over the coming years.
Read more
Investor Relations: the company’s own investor portal provides detailed information on financial results, guidance, share programs and pipeline updates beyond the figures cited here.
Fact box
Company: Novo Nordisk A/S
ISIN: DK0062498333
Ticker: NVO
Exchange: New York Stock Exchange (ADR)
Price (as of August 20, 2026, 4:01 p.m. ET): $46.14 USD
Market cap: not specified in the available sources
Sector / Industry: Health Care / Pharmaceuticals
Index membership: OMX Copenhagen 25
